1. Home
  2. |Insights
  3. |DOJ Allows Hiring of Foreign Official under the FCPA

DOJ Allows Hiring of Foreign Official under the FCPA

Client Alert | 1 min read | 04.23.10

On April 19, 2010, the United States Department of Justice ("DOJ") issued its first FCPA Opinion Procedure Release of 2010, and the first since August 2009.

The Release was requested by a U.S. company ("the Company") (a "domestic concern" within the meaning of the FCPA) which had entered into a contract with a U.S. government agency to design and build a facility in a foreign country. This contract required the Company to hire individuals to work at the facility as directed by the U.S. government agency.

Pursuant to the contract and at the request of the foreign country, the U.S. government agency directed the Company to hire a local individual as the Facility Director. However, this individual was simultaneously serving as a paid officer for an agency of the foreign country's government, and was therefore a "foreign official" under the FCPA.

DOJ opined that it would not pursue an enforcement action under these circumstances since the Company was contractually bound to hire and pay the foreign official, and only did so at the direction of the U.S. Government Agency. Notably, DOJ acknowledged that the individual's services as Facility Director were "separate and apart from" the services performed by the individual as a foreign official. In an apparent nod to the fact that the FCPA only prohibits payments that are made "corruptly," DOJ also noted that the Company would not gain any improper advantage by hiring the Facility Director since the individual did not have any role in matters affecting the Company vis-à-vis his government.

For the release, go to: http://www.justice.gov/criminal/fraud/fcpa/opinion/2010/1001.pdf

Insights

Client Alert | 7 min read | 09.14.26

AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development

Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage. ...